1. Scrip

A simple twist enhances Novo Nordisk's next-generation FlexPen

 
• By John Davis

Novo Nordiskhas announced a number of enhancements to its FlexPen prefilled insulin injection device, which includes a simple twist mechanism to attach and detach needles. This makes it the first pen device able to use a new generation of needles, the company says. Other changes include the need for less force to inject oneself, a single dose-setting mechanism, and a non-medical appearance. FlexPen is the most widely used prefilled insulin device in the world, the company notes.

Novo Nordiskhas announced a number of enhancements to its FlexPen prefilled insulin injection device, which includes a simple twist mechanism to attach and detach needles. This makes it the first pen device able to use a new generation of needles, the company says. Other changes include the need for less force to inject oneself, a single dose-setting mechanism, and a non-medical appearance. FlexPen is the most widely used prefilled insulin device in the world, the company notes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.